INTRODUCTION
Lymphocytic leukemia and lymphomas are malignant neoplasms that disrupt normal lymphocyte development and function.
Lymphocytic leukemia originates in bone marrow and is characterized by high numbers of abnormal lymphocytes in the blood [1] .
Chronic lymphocytic leukemia (CLL) is a slowly progressing disease that affects B lymphocytes (B-cells), mainly in older adults, and is the most common form of leukemia in the Western world, with an annual incidence rate of 4.2 per 100,000 [2] . Lymphomas, on the other hand, encompass a group of hematologic malignancies that arise mainly from mature T lymphocytes (T cells) or B-cells in secondary lymphoid tissue, particularly the lymph nodes [3, 4] . They are subdivided based on the presence of Reed-Sternberg (or Hodgkin) cells into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) [5] , of which NHL is by far the most common (accounting for around 90% of cases) [6] .
There are many types of NHL, differing in terms of microscopic appearance, growth patterns, clinical impact, and treatment [3, 4] .
However, NHL can be broadly divided into two major groups, B-cell and T-cell NHLs, of which the B-cell type accounts for approximately 85% of all cases [5] . Indolent NHL (iNHL) is a slow-growing form of B-cell NHL that includes follicular lymphoma (FL) and marginal zone lymphoma, whereas more aggressive and faster-growing presentations of NHL include diffuse large B-cell lymphoma (DLBCL), Burkitt's lymphoma, and mantle cell lymphoma (MCL) [6] . FL is the most common type of iNHL, with an annual incidence that has risen from 2 to 3 per 100,000 in the 1950s to 5 to 7 per 100,000
more recently in Western Europe [7] . Median age at diagnosis is in the 6th decade of life, but up to 25% of patients with FL are aged 40 years or younger [8] . Approximately 55-70% of patients have bone marrow involvement at presentation, which is indicative of advanced disease [9] [10] [11] . Among aggressive subtypes of NHL, DLBCL is the most prevalent [12], having a crude annual incidence in Europe of 3.8 per 100,000 and accounting for between 30% and 58% of all cases of NHL [13] . Incidence of DLBCL increases with age, and risk factors include a family history of lymphoma, autoimmune disease, human immunodeficiency virus or hepatitis C virus infection, high body mass in young adulthood, and some types of occupational hazard exposure [13] .
Management of NHL and CLL depends on stage, tumor burden, and other patient factors. For example, recent guidelines state that patients with early (stage I-II) iNHL should be offered radiotherapy [8, 14, 15] , which can result in 10-year overall survival (OS) rates of up to 80% [14, 15] . However, most patients with iNHL are incurable [15] , and successive relapses and increasing resistance to treatment characterize the individual course of the disease. Until the late 1990s (i.e., the period preceding the introduction of antibody therapy), these patients were usually treated with increasingly intensive combination chemotherapy regimens to reduce tumor burden and palliate symptoms. Response rates to conventional chemotherapy generally exceeded 50% [12] , and maximal tumor reduction could be achieved with high-dose chemotherapy and autologous stem cell support, but there were no apparent improvements in failure-free survival [16] .
Treatment of symptomatic CLL and the more aggressive forms of NHL have also traditionally relied heavily on intensive combination chemotherapy.
The therapeutic landscape for all forms of B-cell NHL changed markedly in the late 1990s
with the approval of a CD20-directed monoclonal antibody (mAb), rituximab, after demonstration of significant activity as a single agent in patients with iNHL [17, 18] . The antigen CD20 is a membrane protein found on the surface of all mature B-cells that typically has a constitutive and constant expression and therefore provides an excellent therapeutic target [19] . Moreover, it is found in 95% of B-cell malignancies [20] . Rituximab acts by (1960) (1961) (1962) (1963) (1964) (1965) (1966) (1967) (1968) (1969) (1970) (1971) (1972) (1973) (1974) (1975) 180 patients), anthracycline (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) 426 patients), aggressive chemotherapy/purine analogs (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) ; 471 patients), and rituximab (1997) (1998) (1999) (2000) (2001) (2002) (2003) , 257 patients) [22] .
Median OS improved from 11 years in eras 1 and 2 to 18.4 years in era 3; at the time of reporting in 2013, median OS for era 4 had not been reached [22] . The development of rituximab in combination with chemotherapy represented a major step forward, significantly improving survival outcomes in not only patients with FL [23] but also in other CD20-positive B-cell malignancies, including DLBCL [24, 25] and CLL [26] . These advances led to the adoption of rituximab as standard of care in patients with CLL, FL, and DLBCL who require systemic therapy [2, 8, 13, 14] .
Despite the major therapeutic advances brought about by rituximab [15, 27] , relapse and development of resistance to treatment are eventually seen in the majority of B-cell NHL patients [12, 15, 28] . The disease course is characterized thereafter by an ongoing decrease in the quality and duration of response with each subsequent course of therapy [15] . CD20 'shaving' is another potential resistance mechanism to type I anti-CD20 mAbs, whereby mAb-CD20 complexes are rapidly removed from the surface of B-cells via monocytes/macrophages through a mechanism known as trogocytosis [31] [32] [33] . This resistance mechanism can lead to fewer cell-surface CD20 antigens (with a consequent reduction in anti-CD20 mAb binding) and a decrease in Fc-mediated effector functions as well as a reduced mAb half-life. Additionally, there is evidence to indicate that FccRIIb-mediated internalization and degradation of the complex formed between the mAb and CD20 from the surface of some B-cell malignancies may cause resistance to type I anti-CD20 mAbs, such as rituximab [34] [35] [36] Management of relapse and resistance in rituximab-treated patients presents a significant challenge [6] , and there is a need for treatments with improved activity across B-cell NHL subtypes and CLL. Better understanding of antibody biology and modes of action, together with increased ability to design highly efficient therapeutics, has led to the development of novel mAbs with improved activity. As a review article, the following [45] . Ofatumumab also acts primarily via CDC after binding both loop domains of CD20 at a different epitope compared to rituximab [46] .
Increased Direct Cell Death Induction
Obinutuzumab has been shown to be faster than and superior to both rituximab and ofatumumab in inducing direct cell death in [55] .
Complement-Dependent Cytotoxicity
Antibody-mediated CDC is initiated by fixing of C1q (the initiating component of the classical complement pathway) to the Fc portion of target-bound antibodies. This triggers a cascade that in turn leads to the formation of C3 and C5 convertase and ultimately to the membrane attack complex (MAC). The MAC then causes cell lysis by disrupting the plasma membrane of the target cell [62] . Unlike type I anti-CD20 mAbs, type II agents are found to undergo reduced CD20 internalization ( Fig. 1) [67]. Indeed, increased stability of surface-accessible CD20 was noted with obinutuzumab relative to both rituximab and ofatumumab using FACS in a human DLBCL cell line and in blood from patients with CLL [43] . Ultimately, this may further enhance the immune effector cell-mediated mechanisms of type II anti-CD20 mAbs, independently of, but in conjunction with, glycoengineering.
Furthermore, type II anti-CD20 mAbs may be less susceptible to the development of resistance mechanisms affecting effector-cell-mediated cytotoxicity.
The impact of trogocytosis on reducing the efficacy of type II mAbs through shaving of CD20 molecules from the cell surface requires further investigation. 
Each treatment group was compared with its respective vehicle control. TVday z represented TV for an individual animal at a defined study day (day z), and TVday x represented TV of an individual animal at the staging day (day x). Animals in control groups received 0.9% sodium chloride vehicle; randomization to treatments took place 9-27 days after tumor cell injection. Animals were killed at various time points from day 30 to day 66. BEN bendamustine, CHL chlorambucil, FLU fludarabine, G obinutuzumab (GA101), MCL mantle cell lymphoma, RIT rituximab, TGI tumor growth inhibition
Superior Antitumor Efficacy In Vivo cyclophosphamide/vincristine in subcutaneous murine xenograft models using Z138 MCL and WSU-DLCL2 DLBCL tumors [69] . As obinutuzumab had high single-agent activity in these models, suboptimal doses were used in order to observe combination effects. Superior tumor growth inhibition was achieved with obinutuzumab plus bendamustine over rituximab plus bendamustine, and statistically significant effects versus the respective single treatments were also observed ( Fig. 3 ). In addition, obinutuzumab showed significantly greater activity than rituximab when combined with fludarabine, chlorambucil, or cyclophosphamide/ vincristine. Obinutuzumab monotherapy was as effective as, or more effective than, rituximab plus chemotherapy in vivo [69] .
CLINICAL TRIALS OF OBINUTUZUMAB IN B-CELL NHL
Obinutuzumab is now under evaluation in an extensive clinical trial program in patients with B-cell malignancies.
Obinutuzumab Monotherapy
Obinutuzumab given as monotherapy has been investigated in the GAUGUIN study (NCT00517530), a multicenter phase Ib/II clinical trial in patients with B-cell malignancies [70] [71] [72] [73] . The primary objective of the phase Ib part of the study was to investigate the safety and tolerability of escalating intravenous doses of obinutuzumab in patients with CD20-positive lymphoid malignancies, including NHL and CLL. This was followed by a phase II part to study efficacy and safety.
Patients were adults aged 18 years or older with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
The first two reports from GAUGUIN ( Phase II data from relapsed/refractory iNHL patients (n = 40; Table 1 ) showed promising efficacy and acceptable tolerability, particularly in the higher dose group (1600/800 mg) over a median observation time of 33.7 months [71] .
Of the phase II patients, 90% had stage III or IV disease and had received a median of two prior rituximab treatments (range 0-5); 45% and 55% were refractory to their last treatment or to rituximab, respectively. End-of-treatment ORRs in rituximab-refractory patients were 8% in the 400/400 mg group and 50% in the 1600/800 mg group. The two CRs were seen in the higher dosage group.
The phase II GAUGUIN study for patients with aggressive forms of B-cell NHL showed similar tolerability and promising efficacy (Table 1 ) [72] . These patients (25 with DLBCL and 15 with MCL) had received a median of three prior treatments (range 1-17), and 25 (63%) were rituximab-refractory. Of the 25 rituximab-refractory patients, 4 (16%) had objective responses to induction treatment and one responded during follow-up. Four of the five responses were achieved at the 1600/800 mg dose. The best ORR in all patients with aggressive B-cell NHL was 30%.
Median response duration (all responders) was Further data in larger numbers of patients with relapsed iNHL were obtained from the multicenter GAUSS study (NCT00576758) [74] . Table 1 , 175 patients with relapsed iNHL were enrolled to phase II, of whom 149 had FL. The ORR at the end of induction was higher with obinutuzumab than with rituximab, as shown by investigator assessments at the end of the induction period (45% vs. 33%; p = 0.08) and by a blinded independent review panel (45% vs. 27%; p = 0.01) ( Table 1 ). There was no significant difference between treatments for the secondary endpoint of PFS, but the study was not powered to detect differences. AEs were balanced between the two groups, but there were more IRRs and coughs in the obinutuzumab group (Table 1 ) [74] .
An additional phase I study in 12 Japanese patients, of whom 8 had FL, also showed no DLTs [75] . B-cell depletion was seen in all patients and persisted for the duration of treatment. No disease progression was observed during the treatment period.
Moreover, the majority of AEs were of grade 1 or 2 in severity; as in other studies, IRRs predominated (Table 1) . (Table 2 ) [83] . These patients had received up to six prior treatments.
COMBINATION THERAPY
Patients were allocated to either CHOP or FC by their physicians on the basis of clinical need and the physician's judgment; allocation to the two obinutuzumab dose regimens was randomized. As seen in the previously described phase I and II monotherapy studies, IRRs were the most common AEs and were predominantly of mild severity (Table 2) . Two patients from the G-FC 400/400 mg arm and three from the G-FC 1600/800 mg arm discontinued treatment because of AEs; one other patient in the latter group discontinued because of insufficient response. All rituximab-refractory patients responded to treatment, and the high ORRs noted (Table 2 ) supported future phase III investigation [83] .
As G-CHOP was seen to have a safety profile similar to R-CHOP (rituximab combined with CHOP), the design of the GAUDI study was amended to compare the safety of obinutuzumab plus CHOP or bendamustine in 81 treatment-naïve patients with FL (Table 2) [84]. After 2 years' maintenance in initial responders who went on to receive obinutuzumab 1000 mg as monotherapy, high CR rates were seen in both treatment arms and opportunistic infections were infrequent [84] .
G-CHOP was also investigated in the first-line setting in 80 patients with advanced DLBCL in the GATHER study (NCT01414855) ( Table 2) [85]. The ORR and CR rates as determined by investigators were 83% and 55%, respectively (Table 2 ). IRRs, most of which were grade 1-2 in intensity, were typically observed during the first cycle.
Phase III
The phase III GADOLIN study (NCT01059630) ( Where two G doses separated by a forward slash are shown, the first-mentioned dose was given on d1 and the second dose on d8 of the first cycle; the second dose was then given on d1 of the remaining cycles. Unless stated otherwise, eight 21-day cycles of treatment were given (total of nine intravenous infusions) Overall, grade C3 AEs were more common in the obinutuzumab plus bendamustine group, but grade C3 thrombocytopenia and anemia were more frequent in the bendamustine-only group (Table 2) .
Emerging data from GADOLIN also suggest 
In the phase III CLL11 study (Table 3), 781 patients with previously untreated CLL and a score higher than 6 on the Cumulative Illness Rating Scale or an estimated creatinine clearance of 30-69 ml/min were randomized to chlorambucil alone, obinutuzumab plus chlorambucil, or rituximab plus chlorambucil for six 28-day cycles [93]. The main study followed a safety run-in designed to ensure that chlorambucil-containing chemoimmunotherapy regimens were safe in recruited older patients with comorbidities [94] . IRRs and neutropenia were identified as potential risks during the run-in, but none of the specified stopping criteria were met, and the main study was opened for randomization in April 2010.
Both combinations increased PFS significantly over chlorambucil monotherapy; obinutuzumab plus chlorambucil, but not rituximab plus chlorambucil, prolonged OS significantly (Table 3) [95]. Obinutuzumab plus chlorambucil also conferred longer PFS (Table 3) [93, 95] and a higher CR rate (21% vs. 7%) [93] than rituximab plus chlorambucil, and it was associated with significantly and substantially increased time to next treatment (Table 3) [95].
AEs were reported at higher frequencies with obinutuzumab plus chlorambucil than with either of the other two treatments, but toxicities were manageable and the risk of infection was not increased over rituximab plus chlorambucil or chlorambucil alone.
Among patients for whom MRD data were available, the proportion who were MRD-negative in bone marrow and peripheral blood at the end of treatment was markedly higher with obinutuzumab plus chlorambucil than with rituximab plus chlorambucil treatment (bone marrow, 18% vs. 3%; 
SHORTER DURATION OF INFUSION
Reducing the duration of infusion for intravenous drugs has potential advantages in terms of patient and physician burden. Long infusion times and frequent infusion rate changes result in lengthy observation times, increased nursing and administration staff workloads, and inconvenience to patients [103] .
A notable early example of research to balance the benefits of shorter duration of infusion (SDI) against the potentially increased risk of hypersensitivity reactions was the effort made in the 1990s to reduce paclitaxel infusion times from 24 to 3 h [104] . Since then, SDI with rituximab has been investigated in 351 patients with rheumatoid arthritis in the RATE-RA study (NCT01382940): there was no increase in the rate or severity of IRRs when infusion times were reduced from the standard 4.25 to 2 h [103] . SDI with rituximab was subsequently assessed in a phase III study in 425 patients with DLBCL or FL [105] . Reduction of the infusion time from a median of 240 min to a fixed time of 90 min was found to be feasible in patients who tolerated an initial infusion at the longer standard rate. These observations led to an increase in the recommended infusion rate for rituximab to a maximum of 400 mg/h [106] and to the investigation of SDIs in patients receiving obinutuzumab. In the studies in which SDI was investigated, patients received obinutuzumab at the regular infusion rate for the first cycle to establish safety (i.e., no IRRs of grade C3) and activity (lymphocyte count B5000/ll), after which SDI could be started from cycle 2.
GATHER
The safety of SDI of obinutuzumab after cycle 1 was evaluated in the GATHER study (first-line advanced DLBCL) ( GATS Study (JapicCTI-152848)
SDI with obinutuzumab in combination with chemotherapy (CHOP) is also being investigated in a phase II study in Japanese patients ( Table 2) [108] . The creation of a CD19/ CD3 complex brings tumor and T-cells together in close proximity, which in turn activates the T-cell and causes it to destroy the tumor cell via perforin-mediated apoptosis [45] . Other researchers are exploring the potential of anti-CD20/CD3 bispecific antibodies to overcome problems of short half-life in vivo, structural instability, and poor solubility of anti-CD19 BiTEs [109] [110] [111] . Another approach is modification with chimeric antigen receptors (CARs) of T-cells to confer tumor-specific cytotoxicity [112] . Preclinical and clinical studies of CD19 CAR-T-cells have shown encouraging results in a variety of cancers, particularly B-cell hematologic malignancies [113] .
There is also a need to explore the potential applicability of surrogate endpoints in hematologic malignancies to help direct therapy and to expedite the conduct of clinical trials. Positron emission tomography using 18-fluoro-2-deoxyglucose has become a standard clinical tool for staging and response assessment in aggressive lymphomas, and results from a number of studies indicate its potential utility in predicting outcomes in patients with DLBCL and FL [114, 115] .
Another approach is to measure MRD (as described above for GADOLIN and CLL11) patients with individual patient data has supported this hypothesis [117] : an absolute improvement in CR30 of C10% over a control CR30 of 50% predicted a significant improvement in PFS. This suggests that CR30
has utility as a surrogate for PFS in first-line FL trials and supports its use to facilitate treatment development.
In conclusion, researchers are continuing their efforts to develop increasingly efficient therapies that provide long treatment-free periods for patients with relapsing or refractory disease, to identify the most effective combination therapies (notably triplet combinations) and, as discussed above, to develop chemotherapy-free regimens based on immunotherapy. The advances with obinutuzumab described here against the background of the many other therapeutic approaches that are underway are evidence of marked and significant progress in the development and application of immunotherapy against lymphocytic leukemia and B-cell lymphoma.
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